0001213900-21-018959 | 20-F | XBRL Viewer | Auris Medical Holding LTD

SFr 4,353

SFr 2,110,728

Financing Cash Flows

^[1]

1,522,931

(1,463,328)

Fair value revaluation

219,315

(663,725)

Other changes

^[2]

(905,922)

20,678

Derivative financial instrument [Member]

840,677

4,353

Financial instruments and risk management (Details) - Schedule of fair value measurement of derivative financial instrument [Line Items]

4,353

675,328

Financing Cash Flows

^[1]

Fair value revaluation

219,315

(663,725)

Other changes

^[2]

93,089

(7,250)

Financial instruments and risk management (Details) - Schedule of fair value measurement of derivative financial instrument [Line Items]

316,757

4,353

Loans [Member]

1,435,400

Financing Cash Flows

^[1]

1,522,931

(1,463,328)

Fair value revaluation

Other changes

^[2]

(999,011)

27,928

One Year Vesting Period [Member] | Equity Incentive Plan 2020 [Member]

SFr 523,920

[1]	The financing cash flows are from loan borrowings or loan repayments.
[2]	Other non-cash changes include recognition of derivative, partial conversion and amortization of convertible loan, accrued interest and Foreign Exchange-Difference.

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Financial instruments and risk management (Details) - Schedule of carrying amounts of financial assets and financial liabilities - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Financial instruments and risk management (Details) - Schedule of carrying amounts of financial assets and financial liabilities [Line Items]
Maximum exposure to credit risk	$ 11,268,910	$ 1,464,760
Cash and cash equivalents [Member]
Financial instruments and risk management (Details) - Schedule of carrying amounts of financial assets and financial liabilities [Line Items]
Maximum exposure to credit risk	11,258,870	1,384,720
Other receivables [Member]
Financial instruments and risk management (Details) - Schedule of carrying amounts of financial assets and financial liabilities [Line Items]
Maximum exposure to credit risk	$ 10,040	$ 80,040

Financial instruments and risk management (Details) - Schedule of quantitative data about the exposure of financial assets and liabilities to currency risk	Dec. 31, 2020 EUR (€)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 EUR (€)	Dec. 31, 2019 USD ($)
Financial instruments and risk management (Details) - Schedule of quantitative data about the exposure of financial assets and liabilities to currency risk [Line Items]
Net statement of financial position exposure -asset/(liability)	€ (272,966)	$ 9,104,828	€ (576,832)	$ 393,282
Trade and other payables [Member]
Financial instruments and risk management (Details) - Schedule of quantitative data about the exposure of financial assets and liabilities to currency risk [Line Items]
Net statement of financial position exposure -asset/(liability)	(397,853)	(75,712)	(526,637)	(51,527)
Accrued Expenses [Member]
Financial instruments and risk management (Details) - Schedule of quantitative data about the exposure of financial assets and liabilities to currency risk [Line Items]
Net statement of financial position exposure -asset/(liability)	(569,400)	(34,648)	(175,826)	(750,949)
Cash and Cash Equivalents [Member]
Financial instruments and risk management (Details) - Schedule of quantitative data about the exposure of financial assets and liabilities to currency risk [Line Items]
Net statement of financial position exposure -asset/(liability)	€ 694,287	9,214,709	125,631	1,041,695
Other Receivables [Member]
Financial instruments and risk management (Details) - Schedule of quantitative data about the exposure of financial assets and liabilities to currency risk [Line Items]
Net statement of financial position exposure -asset/(liability)		$ 479		$ 154,063

Segment information (Details) - Schedule of operating segments - CHF (SFr)	Dec. 31, 2020	Dec. 31, 2019
Segment information (Details) - Schedule of operating segments [Line Items]
Non-current assets	SFr 9,182,047	SFr 6,852,286
Switzerland [Member]
Segment information (Details) - Schedule of operating segments [Line Items]
Non-current assets	9,030,778	SFr 6,852,286
Australia [Member]
Segment information (Details) - Schedule of operating segments [Line Items]
Non-current assets	SFr 151,269

Property and Equipment (Details) - Schedule of property, plant and equipment - CHF (SFr)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
At cost [Member]
Property and Equipment (Details) - Schedule of property, plant and equipment [Line Items]
Property, plant and equipment	SFr 587,194	SFr 523,594
Additions		63,600
Disposals
Property, plant and equipment	587,194	587,194
Accumulated depreciation [Member]
Property and Equipment (Details) - Schedule of property, plant and equipment [Line Items]
Property, plant and equipment	(520,522)	(489,699)
Additions	(20,036)	(30,823)
Disposals
Property, plant and equipment	(540,558)	(520,522)
Net book value [Member]
Property and Equipment (Details) - Schedule of property, plant and equipment [Line Items]
Property, plant and equipment	66,672
Property, plant and equipment	46,636	66,672
Production equipment [Member] \| At cost [Member]
Property and Equipment (Details) - Schedule of property, plant and equipment [Line Items]
Property, plant and equipment	353,488	289,888
Additions		63,600
Disposals
Property, plant and equipment	353,488	353,488
Production equipment [Member] \| Accumulated depreciation [Member]
Property and Equipment (Details) - Schedule of property, plant and equipment [Line Items]
Property, plant and equipment	(290,491)	(270,408)
Additions	(16,481)	(20,083)
Disposals
Property, plant and equipment	(306,972)	(290,491)
Production equipment [Member] \| Net book value [Member]
Property and Equipment (Details) - Schedule of property, plant and equipment [Line Items]
Property, plant and equipment	62,997
Property, plant and equipment	46,516	62,997
Office furniture and EDP [Member] \| At cost [Member]
Property and Equipment (Details) - Schedule of property, plant and equipment [Line Items]
Property, plant and equipment	233,706	233,706
Additions
Disposals
Property, plant and equipment	233,706	233,706
Office furniture and EDP [Member] \| Accumulated depreciation [Member]
Property and Equipment (Details) - Schedule of property, plant and equipment [Line Items]
Property, plant and equipment	(230,031)	(219,291)
Additions	(3,555)	(10,740)
Disposals
Property, plant and equipment	(233,586)	(230,031)
Office furniture and EDP [Member] \| Net book value [Member]
Property and Equipment (Details) - Schedule of property, plant and equipment [Line Items]
Property, plant and equipment	3,675
Property, plant and equipment	SFr 120	SFr 3,675

Intangible assets (Details) - CHF (SFr)	12 Months Ended
Intangible assets (Details) - CHF (SFr)	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2013	Dec. 06, 2018	Jul. 30, 2017
Intangible assets (Details) [Line Items]
Capitalize prosecution and registration costs	SFr 177,623	SFr 239,593
Capitalized amount	SFr 2,343,677	SFr 3,230,373
License [Member] \| At cost [Member]
Intangible assets (Details) [Line Items]
Milestone payment intangible			SFr 1,125,000
IP & Data rights [Member]
Intangible assets (Details) [Line Items]
Intangible assets				SFr 47,409
IP & Data rights [Member] \| At cost [Member]
Intangible assets (Details) [Line Items]
Intangible assets					SFr 146,580

Other receivables (Details) - Schedule of other receivables - CHF (SFr)	Dec. 31, 2020	Dec. 31, 2019
Schedule of other receivables [Abstract]
Advance payments to suppliers	SFr 479
Value added tax receivable	38,337	SFr 26,438
Withholding tax receivable	6,087	24,113
Deposit credit cards	10,040	80,040
Other	25,918	204,708
Total other receivables	SFr 80,861	SFr 335,299

Prepayments (Details) - Schedule of prepayments - CHF (SFr)	Dec. 31, 2020	Dec. 31, 2019
Schedule of prepayments [Abstract]
Advance payments to suppliers	SFr 5,020	SFr 40,461
Clinical projects and related activities	164,916	265,842
Insurance	104,590	114,016
Other	3,063	13,912
Total prepayments	SFr 277,589	SFr 434,231

Cash and cash equivalents (Details) - Schedule of cash and cash equivalents - CHF (SFr)	Dec. 31, 2020	Dec. 31, 2019
Schedule of cash and cash equivalents [Abstract]
Cash in bank accounts	SFr 11,258,870	SFr 1,383,182
Cash on hand		1,538
Total cash and cash equivalents	SFr 11,258,870	SFr 1,384,720

Capital and reserves (Details) $ / shares in Units, $ in Millions								1 Months Ended	12 Months Ended
	Dec. 03, 2020	Dec. 01, 2020 CHF (SFr) shares	May 15, 2019	Jan. 24, 2019	Dec. 11, 2018	May 02, 2018	Jan. 30, 2018	Apr. 23, 2020	Dec. 31, 2020 CHF (SFr) shares	Dec. 31, 2020 USD ($) shares	Jul. 17, 2018	Dec. 01, 2020 $ / shares
Disclosure of share capital, reserves and other equity interest [text block] [Abstract]
Securities purchase agreements description	the Company entered into securities purchase agreements with several institutional investors for the purchase and sale of 2,000,000 common shares at an offering price of $4.00 per share, pursuant to a registered direct offering. The net proceeds of the offering were approximately $7.3 million.
Conversion amount \| SFr		SFr 895,455
Conversion shares		737,000
Conversion price \| $ / shares												$ 1.35
Description of purchase agreement								Pursuant to the purchase agreement, LPC agreed to subscribe for up to USD 10,000,000 of our common shares over the 30-month term of the purchase agreement. In 2020, we issued 1,200,000 of our common shares to LPC for an aggregate amount of USD 1.1 million. The 2020 Commitment Purchase Agreement replaced the 2018 Commitment Purchase Agreement. Under the 2018 Commitment Purchase Agreement agreed to purchase common shares for up to $10,000,000 over the 30-month term of the Purchase Agreement. Prior to its termination we had issued 587,500 common shares for aggregate proceeds of $1.8 million to LPC under the LPC Purchase Agreement. The Purchase Agreement replaced the Purchase Agreement that we entered into with LPC on October 10, 2017 (the “2017 Commitment Purchase Agreement”), which was terminated as a result of the Merger. Under the 2017 Commitment Purchase Agreement, LPC agreed to subscribe for up to $13,500,000 of our common shares, and prior to its termination, we had issued an aggregate of 2,600,000 (pre-merger) common shares for aggregate proceeds of $1.8 million to LPC under the 2017 Commitment Purchase Agreement.
Description of public offering			the Company completed a public offering of (i) 440,000 common shares with a par value of CHF 0.40 each, together with warrants to purchase 440,000 common shares, and (ii) 1,721,280 pre-funded warrants, with each pre-funded warrant exercisable for one common share, together with warrants to purchase 1,721,280 common shares, including 110,000 common shares and warrants to purchase 110,000 common shares sold pursuant to a partial exercise by the underwriters of the underwriters’ over-allotment option (the “May 2019 Registered Offering”). The exercise price for the pre-funded warrants was CHF 0.01 per common share and for the warrants CHF 4.34. The net proceeds to us from the May 2019 Registered Offering were approximately $7.7 million, after deducting underwriting discounts and other offering expenses payable by us. All pre-funded warrants were exercised in 2019. In December 2020, 1,263,845 warrants were exercised, leaving 897,435 warrants outstanding as of December 31, 2020. These remaining warrants were exercised in March 2021.								the Company completed a public offering of 897,435 common shares with a nominal value of CHF 0.40, Series A warrants each entitling its holder to purchase 0.35 of a common share for an aggregate of 314,102 common shares, and Series B warrants entitling its holder to purchase 0.25 of a common share for an aggregate of 224,358 common shares (the “July 2018 Registered Offering”). As of December 31, 2019, the exercise price for the Series A Warrants was CHF 7.80 per common share and the exercise price for the Series B Warrants was CHF 3.95 per common share (which exercise price was automatically adjusted due to the May 2019 Registered Offering). Since the July 2018 Registered Offering, certain Series A warrant holders exercised their warrant shares to purchase 145,226 common shares of the Company and certain Series B warrant holders exercised warrant shares to purchase 143,221 common shares. On June 30, 2020, the Series B warrants expired without further warrants being exercised. The net proceeds to the Company from the July 2018 Registered Offering were approximately CHF 6.2 million, after deducting underwriting discounts and other offering expenses payable by us. The Company had transaction costs amounting to CHF 851,692. The transaction costs were recorded as CHF 742,833 in equity for the issuance of common shares and CHF 108,809 to finance expense in the statement of profit or loss and comprehensive loss for the issuance of the warrants.
Offering price \| $										$ 25.0
Sale of common stock									1,628,827	1,628,827
Common shares for an aggregate									1,758,618	1,758,618
Aggregate offering price \| $										$ 3.2
Sale of stock									98,954	98,954
Aggregate offering price \| $										$ 978,415.0
Transaction costs \| SFr									SFr 71,161
Commitment purchase agreement, description					On November 27, 2018 and December 11, 2018, the Company entered into purchase agreements with FiveT Capital AG, providing for the issuance and sale by us of an aggregate of 165,750 of its common shares for an aggregate purchase price of CHF 1.6 million in two separate registered direct offerings.	the compnay entered into a purchase agreement (the “2018 Commitment Purchase Agreement”) and a registration rights agreement (the “2018 Registration Rights Agreement”) with Lincoln Park Capital LLC (“LPC”). Pursuant to the 2018 Commitment Purchase Agreement, LPC agreed to purchase common shares for up to $10,000,000 over the 30-month term of the 2018 Commitment Purchase Agreement. As of the date of these consolidated financial statements, the Company has issued an aggregate of 89,880 common shares for aggregate proceeds of CHF 286,450 to LPC under the 2018 Commitment Purchase Agreement. The 2018 Commitment Purchase Agreement replaces the 2017 Commitment Purchase Agreement (as defined below), which was terminated as a result of the Merger. Under the 2017 Commitment Purchase Agreement, LPC agreed to subscribe for up to $13,500,000 common shares and prior to its termination, the Company had issued an aggregate of 2,600,000 (pre-merger) common shares for aggregate proceeds of CHF 1.7 million to LPC under the 2017 Commitment Purchase Agreement. The Company had transaction costs amounting to CHF 349,907. The payment of CHF 252,351 was recorded as a derivative financial instrument and classified as a non-current asset and CHF 97,556 to finance expense in the statement of profit or loss and comprehensive loss. During the financial year 2019, the Company had sold 89,880 of its common shares for an aggregate offering price of $ 286,450. The related transaction costs of CHF 2,859 were charged to equity.
Description of Memorandum of Continuance				The Company’s Memorandum of Continuance and the Bye-laws that were adopted at an extraordinary meeting of shareholders held on March 8, 2019 provided for an authorized share capital of 200,000,000 common shares and 20,000,000 preference shares. Following a reverse share split at a ratio of 20-for-1 on May 1, 2019, a decision by the annual general meeting of shareholders on June 4, 2020 to increase the authorized share capital and the reduction of the par value of June 30, 2020, our authorized share capital consists of 25,000,000 common shares, par value CHF 0.01 per share, and 20,000,000 preference shares, par value CHF 0.02 per share.			the Company completed a public offering of 62,499 common shares and concurrent offering of warrants, each warrant entitling its holder to purchase 0.6 common shares (the “January 2018 Registered Offering”). The net proceeds to the Company from the January 2018 Registered Offering were approximately CHF 4.5 million, after deducting placement agent fees and other estimated offering expenses payable by the Company. As of December 31, 2020, the outstanding warrants issued in the January 2018 Registered Offering were exercisable for up to 37,501 common shares (assuming the Company rounds up fractional common shares to the next whole common share) at an exercise price of $100.00 per common share. As of December 31, 2019 the outstanding warrants were exercisable for up to 37,501 common shares at an exercise price of $100.00 per common share. The Company had transaction costs amounting to CHF 654,985. The transaction costs were recorded as CHF 341,226 in equity for the issuance of the common shares and CHF 313,760 to finance expense in the statement of profit or loss and comprehensive loss for the issuance of the warrants.

Capital and reserves (Details) - Schedule of issued share capital - CHF (SFr)	Dec. 31, 2020	Dec. 31, 2019
Capital and reserves (Details) - Schedule of issued share capital [Line Items]
Number	11,417,159	4,125,949
Value (CHF)	SFr 114,172	SFr 1,650,380
Ordinary Shares [Member]
Capital and reserves (Details) - Schedule of issued share capital [Line Items]
Number	11,417,159
Value (CHF)	SFr 114,172
Ordinary Shares Nominal Value [member]
Capital and reserves (Details) - Schedule of issued share capital [Line Items]
Number		4,125,949
Value (CHF)		SFr 1,650,380

Capital and reserves (Details) - Schedule of issued share capital (Parentheticals) - SFr / shares	Dec. 31, 2020	Dec. 31, 2019
Ordinary Shares [Member]
Capital and reserves (Details) - Schedule of issued share capital (Parentheticals) [Line Items]
Nominal value of common shares	SFr 0.01	SFr 0.01
Ordinary Shares Nominal Value [member]
Capital and reserves (Details) - Schedule of issued share capital (Parentheticals) [Line Items]
Nominal value of common shares	SFr 0.40	SFr 0.40

Capital and reserves (Details) - Schedule of common shares - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Schedule of common shares [Abstract]
Beginning balance	4,125,949	1,775,839
Ending balance	11,417,159	4,125,949
Public offering		2,161,280
Exercise of warrants	1,263,845
LPC equity line	1,610,120	89,880
ATM program	1,628,827	98,950
Share-based payments (bonus)	51,418
Conversion convertible loan	737,000
Registered direct offering	2,000,000

Share-based compensation (Details)	12 Months Ended
Share-based compensation (Details)	Dec. 31, 2020 CHF (SFr) SFr / shares shares	Dec. 31, 2019 CHF (SFr) SFr / shares shares	Dec. 31, 2018 CHF (SFr)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Share-based compensation (Details) [Line Items]
Options granted (in Shares) \| shares	726,637	390,620
Share based payment \| SFr	SFr 368,793	SFr 228,920	SFr 42,757
Total expense recognized for equity-settled share-based payment transactions \| SFr	SFr 351,401	SFr 226,601	27,730
Purchase of intangibles was capitalized			SFr 15,027	$ 0	$ 2,319
Bottom of range [member]
Share-based compensation (Details) [Line Items]
Stock options exercise price (in Francs per share) \| SFr / shares	SFr 0.73	SFr 2.00
Top of range [member]
Share-based compensation (Details) [Line Items]
Stock options exercise price (in Francs per share) \| SFr / shares	SFr 27.93	SFr 5.56

Share-based compensation (Details) - Schedule of key terms and conditions related to the grants	12 Months Ended
	Dec. 31, 2020
Share-based compensation (Details) - Schedule of key terms and conditions related to the grants [Line Items]
Number of options outstanding	237,083
Vesting conditions	1 year service from grant date
Contractual life of options	6 years
Equity Incentive Plan Employees / Board [Member]
Share-based compensation (Details) - Schedule of key terms and conditions related to the grants [Line Items]
Number of options outstanding	399,738
Vesting conditions	2 years' service from grant date (50%)
Contractual life of options	8 years
Equity Incentive Plan Employees / Board One [Member]
Share-based compensation (Details) - Schedule of key terms and conditions related to the grants [Line Items]
Number of options outstanding	399,738
Vesting conditions	3 years' service from grant date (50%)
Contractual life of options	8 years

Share-based compensation (Details) - Schedule of fair value of the options measured - USD ($)

12 Months Ended

Dec. 31, 2020

Dec. 31, 2019

Share-based compensation (Details) - Schedule of fair value of the options measured [Line Items]

^[1]

USD 0.325 (2 year vesting) 1) USD 0.391 (3 year vesting) 1)

USD 0.79

USD 0.878

84.96%

2 and 3 years

One Year Vesting Period [Member] | Equity Incentive Plan 2019 [Member]

0.82%

Share-based compensation (Details) - Schedule of fair value of the options measured [Line Items]

^[1]

USD 0.715 (1 year vesting) 1) USD 1.006 (2 year vesting) 1) USD 1.193 (3 year vesting) 1)

USD 1.76

USD 2.07

119.41%

1, 2 and 3 years

Two Year Vesting Period [Member] | Equity Incentive Plan 2020 [Member]

1.62%

Share-based compensation (Details) - Schedule of fair value of the options measured [Line Items]

^[2]

USD 0.258 (1 year vesting) 2) USD 0.514 (2 year vesting) 2) USD 0.578 (3 year vesting) 2)

USD 0.92

USD 0.825

72.72%

1, 2 and 3 years

Two Year Vesting Period [Member] | Equity Incentive Plan 2019 [Member]

0.61%

Share-based compensation (Details) - Schedule of fair value of the options measured [Line Items]

^[2]

USD 1.495 (1 year vesting) 2) USD 2.196 (2 year vesting) 2) USD 2.596 (3 year vesting) 2)

USD 3.35

USD 5.75

156.26%

1, 2 and 3 years